Cryo-Cell International Inc 2026年季度报告

FORM 10-Q (Mark One)☒Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. CRYO-CELL INTERNATIONAL, INC.(Exact name of Registrant as Specified in its Charter) DELAWARE(State or other Jurisdiction ofIncorporation or Organization) 22-3023093(I.R.S. EmployerIdentification No.) 700 Brooker Creek Blvd. Oldsmar, FL 34677(Address of Principal Executive Offices) (Zip Code) Issuer's phone number, including area code: (813) 749-2100 (Former name, former address and former fiscal year, if changed since last report). Securities registered pursuant to Section 12(b) of the Act: Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted andposted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit and post such files.Yes☒No☐Not Applicable☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smallerreporting company. See definition of “large accelerated filer,” “accelerated filer,” “small reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer☐Non-accelerated filer☑ Accelerated filer☐Smaller reporting company☑Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)☐ Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As ofApril 14, 2026, 8,055,150 shares of $0.01 par value common stock were outstanding. CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES TABLE OF CONTENTS PART I - FINANCIAL INFORMATION (UNAUDITED) Item 1. Financial StatementsConsolidated Balance Sheets3Consolidated Statements of Income4Consolidated Statements of Cash Flows5Consolidated Statements of Stockholders’ Deficit6Notes to Consolidated Financial Statements7Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations26Item 3. Quantitative and Qualitative Disclosures about Market Risk34Item 4. Controls and Procedures34PART II - OTHER INFORMATION36Item 1. Legal Proceedings36Item 1A. Risk Factors36Item 2. Unregistered Sales of Equity Securities and Use of Proceeds37Item 3. Defaults Upon Senior Securities37Item 4. Mine Safety Disclosures37Item 5. Other Information37Item 6. Exhibits39SIGNATURES40 CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF INCOME(Unaudited) The accompanying notes are an integral part of these consolidated financial statements. CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT(Unaudited) The accompanying notes are an integral part of these consolidated financial statements. CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTSFebruary 28, 2026(Unaudited) Note 1 - Description of Business, Basis of Presentation and Significant Accounting Policies Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and isheadquartered in Oldsmar, Florida. The Company is organized in three reportable segments: (1) cellular processing and cryogeniccellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use (2) themanufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and (3) cryogenicstorage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storagerepresent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cordblood stem cells program to customers outside the United States. Revenues for the manufacture of PrepaCyte CB units representsales of the PrepaCyte CB units to customers. Revenue for the cryogenic storage of umbilical cord blood stem cells for public use,stored at Duke University (see below), is generated from the sale of the cord blood units to the National Marrow Donor Program(“NM